Your browser doesn't support javascript.
loading
Discovery of a chemical probe for PRDM9.
Allali-Hassani, Abdellah; Szewczyk, Magdalena M; Ivanochko, Danton; Organ, Shawna L; Bok, Jabez; Ho, Jessica Sook Yuin; Gay, Florence P H; Li, Fengling; Blazer, Levi; Eram, Mohammad S; Halabelian, Levon; Dilworth, David; Luciani, Genna M; Lima-Fernandes, Evelyne; Wu, Qin; Loppnau, Peter; Palmer, Nathan; Talib, S Zakiah A; Brown, Peter J; Schapira, Matthieu; Kaldis, Philipp; O'Hagan, Ronan C; Guccione, Ernesto; Barsyte-Lovejoy, Dalia; Arrowsmith, Cheryl H; Sanders, John M; Kattar, Solomon D; Bennett, D Jonathan; Nicholson, Benjamin; Vedadi, Masoud.
Afiliação
  • Allali-Hassani A; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Szewczyk MM; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Ivanochko D; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Organ SL; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, ON, M5G 2M9, Canada.
  • Bok J; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Ho JSY; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Gay FPH; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Li F; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Blazer L; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Eram MS; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Halabelian L; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Dilworth D; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Luciani GM; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Lima-Fernandes E; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Wu Q; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Loppnau P; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Palmer N; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Talib SZA; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Brown PJ; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Schapira M; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Kaldis P; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • O'Hagan RC; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
  • Guccione E; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Barsyte-Lovejoy D; National University of Singapore (NUS), Department of Biochemistry, 117597, Singapore, Singapore.
  • Arrowsmith CH; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
  • Sanders JM; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Kattar SD; Department of Oncological Sciences and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Bennett DJ; Department of Pharmacological Sciences and Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Nicholson B; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
  • Vedadi M; Nature Research Center, Vilnius, Akademijos, 2, Lithuania.
Nat Commun ; 10(1): 5759, 2019 12 17.
Article em En | MEDLINE | ID: mdl-31848333
PRDM9 is a PR domain containing protein which trimethylates histone 3 on lysine 4 and 36. Its normal expression is restricted to germ cells and attenuation of its activity results in altered meiotic gene transcription, impairment of double-stranded breaks and pairing between homologous chromosomes. There is growing evidence for a role of aberrant expression of PRDM9 in oncogenesis and genome instability. Here we report the discovery of MRK-740, a potent (IC50: 80 ± 16 nM), selective and cell-active PRDM9 inhibitor (Chemical Probe). MRK-740 binds in the substrate-binding pocket, with unusually extensive interactions with the cofactor S-adenosylmethionine (SAM), conferring SAM-dependent substrate-competitive inhibition. In cells, MRK-740 specifically and directly inhibits H3K4 methylation at endogenous PRDM9 target loci, whereas the closely related inactive control compound, MRK-740-NC, does not. The discovery of MRK-740 as a chemical probe for the PRDM subfamily of methyltransferases highlights the potential for exploiting SAM in targeting SAM-dependent methyltransferases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sondas Moleculares / Histona-Lisina N-Metiltransferase / Inibidores Enzimáticos / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sondas Moleculares / Histona-Lisina N-Metiltransferase / Inibidores Enzimáticos / Descoberta de Drogas Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article